Latest News and Insights

Articles, Interviews & Publications

Interviews and Podcasts

Psychedelic Vantage Interview

Podcast

October 2024

Chris Witowski, PhD was featured on the Pharmaverse Podcast hosted by Michael Pietrack. The podcast shines a light on insights and perspectives from influential and innovative leaders in the pharmaceutical and biotech industries. In their discussion, Michael and Chris discussed how we as researchers are currently in the renaissance of neurology and how Psilera is pioneering next-generation psychedelic medicines, including neuroplastogens.

Listen

Psychedelic Vantage Interview

Podcast

August 2024

Jake Slomowitz from Psychedelic Vantage had an in depth conversation with Chris Witowski, PhD highlighting our CEO’s passions in research and drug development. Psilera’s focus on creating non-hallucinogenic neuroplastogens was of particular interest to Slomowitz and illustrates how we as a company are evolving within the industry to meet the needs of a wider variety of patients.

The Trip Report: Beckley Waves

Podcast

April 2024

Dr. Jackie von Salm sat down with Zach Haigney from the Psychedelic Venture Studio to discuss the drug discovery process. They also discuss how 2 Bromo-LSD, a non-hallucinogenic compound that has been successfully used by people suffering from cluster headaches, among other neurological conditions inspired Psilera to push the bounds on what next-generation psychedelics can do patients in need.

Listen
Listen

Press Releases

2025

2024

Psilera Recieves Positive Preclinical In Vivo Data for FTD Candidate PSIL-006

2023

Psilera Receives Allowance on Flagship Patent Securing Novel Compound Library
Psilera Unveils Psilocybin Derivative PSIL-006 As Lead Clinical Candidate
Non-Hallucinogenic Drug Candidates for First-in-Human Studies
Psilera Co-Founders' Summer Conference Announcement
Psilera Presenting on International Stage at Biotech Showcase

2022

Psilera Inc. & atai Life Sciences Announce Licensing Agreement for DMT Patent Portfolio
USF Research Foundation Proudly Endorses and Invests In Psilera's FTD Research
First Patent Allowance for Transdermal Patch Formulations
2022 Wall Street Journal Health Forum and American Chemical Society Meeting
Dr. Magali Haas, M.D., Ph.D. Joins Psilera as an Independent Board Member
USF and Morsani College of Medicine Funding Match for NCE's
Press Kit